NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

RecruitingPhase 3

Sponsor: Fu Jen Catholic University Hospital

Conditions: GLP-1

Interventions: Stop for 1 week, GLP-1 non stop

Countries: Taiwan

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

Eligibility overview

Sex: ALL

Age: 18 Years to 90 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).

  * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.
  * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.
  * Age between 18 and 70 years.
  * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  * Provision of written informed consent.
  * Outpatient status.
  * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.

Exclusion Criteria:

* • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).

  * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).
  * Any other condition deemed inappropriate by the treating physician.
  * Body mass index (BMI) \> 40 kg/m².
  * Liver cirrhosis.
  * Parkinson's disease.
  * Dementia.
  * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Locations (1)

New Taipei City, Taiwan, Taiwan